Prime Medicine (PRME) reported a Q3 loss late Thursday of $0.22 per diluted share, narrowing from the loss of $0.32 a year earlier.
Analysts polled by FactSet expected a loss of $0.24.
Revenue in the three months ended Sept. 30 rose to $4.21 million from $1.23 million a year earlier.
Analysts projected $1.3 million.
The company closed its public offering of about 41.1 million common shares at $3.50 each for gross proceeds of roughly $143.7 million.
Prime Medicine shares rose 3.6% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments